Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

48 results about "Anti hyperglycemic" patented technology

Antihyperglycemic agent. /an·ti·hy·per·gly·ce·mic/ (-gli-se´mik) counteracting high levels of glucose in the blood, or an agent that so acts. [an′te-, an′ti-hi′per-gli-se′mik] 1 pertaining to a substance or therapy that counteracts high levels of glucose in the blood.

Controlled release metformin formulations

Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration.
Owner:ANDRX LABS

Controlled release oral tablet having a unitary core

A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.
Owner:ANDRX LABS

Oxadiazolidinedione compound

A pharmaceutical agent having GPR40 receptor agonistic action, particularly a compound which is useful as an insulin secretagogue or an agent for preventing and / or treating diabetes mellitus. The present inventors have examined a compound having GPR40 receptor agonistic action, confirmed that an oxadiazolidinedione compound which has a substituent such as a benzyl group, etc. linked with a substituent such as a phenyl group, etc. through a linker at the 2-position of an oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof has an excellent GPR40 agonistic activity, and thus completed the invention. The oxadiazolidinedione compound has excellent insulin secretagogue action and anti-hyperglycemic action, and therefore can be used as an insulin secretagogue or an agent for preventing and / or treating diabetes mellitus.
Owner:ASTELLAS PHARMA INC

Single daily dosage form for prevention and treatment of metabolic syndrome

The present invention is in the fields of medicine, pharmaceuticals, nutraceuticals, endocrinology and cardiology. The invention provides compositions comprising a statin, an inhibitor of the angiotensin converting enzyme, an antiplatelet compound and an anti-hyperglycemic compound for use in the treatment and / or prevention of cardiometabolic risk factors of Metabolic Syndrome and treatment and / or prevention of Metabolic Syndrome. The present invention provides for the use of such compositions in the manufacture of products for treatment and / or prevention of Metabolic Syndrome. The biguanide metformin of the composition could be present in extended release form allowing its use together with the other drugs in a single dosage form at low dose. This combination of drugs in a single daily dosage greatly improves compliance and adherence to treatment which is a critical factor for treating patients with Metabolic Syndrome.
Owner:NUCITEC DE C V

Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity

ActiveUS7268157B2Decrease hyperglycemiaDecrease hypertriglyceremiaBiocideOrganic chemistryAcute hyperglycaemiaCoronary artery disease
Disclosed is the preparation and pharmaceutical use of substituted arylalcanoic acid derivatives of Formula I, wherein ring A, ring B, R1, R2, R3, R4, R5, X, Alk1, Alk2, Ar1, and Ar2 are as defined in the specification. These compounds, as selective agonists activating peroxisome proliferator-activated receptors (PPAR), in particularly the RXR / PPARalpha, RXR / PPARgamma, and RXR / PPARdelta heterodimers, are useful in the treatment and / or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders with improved side effects profile commonly associated with conventional PPARgamma agonists.
Owner:SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD

Preparation method for black fungus blood fat-reducing products

The invention relates to a method for preparing black edible fungus anti-hyperglycemic product, belonging to field of preparing polysaccharide. The invention employs black edible fungus deep level liquid fermentation technique, extracts inter-cellular and extra-cellular polysaccharide from deep level fermentation culture, and getting final product through preparation with cell wall-broken treated black edible fungus powder. The product is characterized by apparent functions of reducing serum cholesterol, triglyceride and low-density lipoprotein, and can be used for subsidiary treatment or prevention for hyperlipoidemia.
Owner:GUANGDONG YUEWEI EDIBLE FUNGI TECH

Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.
Owner:ACTAVIS HOLDCO US INC

Single Daily Dosage Form for Prevention and Treatment of Metabolic Syndrome

The present invention is in the fields of medicine, pharmaceuticals, nutraceuticals, endocrinology and cardiology. The invention provides compositions comprising a statin, an inhibitor of the angiotensin converting enzyme, an antiplatelet compound and an anti-hyperglycemic compound for use in the treatment and / or prevention of cardiometabolic risk factors of Metabolic Syndrome and treatment and / or prevention of Metabolic Syndrome. The present invention provides for the use of such compositions in the manufacture of products for treatment and / or prevention of Metabolic Syndrome. The biguanide metformin of the composition could be present in extended release form allowing its use together with the other drugs in a single dosage form at low dose. This combination of drugs in a single daily dosage greatly improves compliance and adherence to treatment which is a critical factor for treating patients with Metabolic Syndrome.
Owner:NUCITEC DE C V

Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents

The present invention provides novel substituted chalcone derivatives which exhibit anti-hyperglycemic and anti-dyslipedemic activity. The invention also provides a method for treating type II diabetes and associated hyperlipidemic conditions in a mammal by administering the compounds of the present invention and compositions containing these derivatives.
Owner:PRATAP RAM +8

Intestinal alpha-glucosidase inhibitors and a process for the isolation and use thereof

This invention provides a-glucosidase inhibitors isolated from Oroxylum indicum an Indian medicinal plant. Particularly, this invention provides hexane and acetone fraction of Oroxylum indicum wherein the hexane fraction comprises a-glucosidase active compounds of oroxylin A, chrysin and baicalain and acetone fraction comprises the compounds of oroxylin A, chrysin, baicalain, methoxy chrysin and oroxyloside methyl ester. This invention also relates to a process for the isolation of a-glucosidase inhibitory active compounds from the above said hexane and acetone fraction of Oroxylum indicum. This invention also provides the use of potent intestinal a-glucosidase inhibitors as active ingredients that can be used in pharmaceuticals, food products, health foods and specialized health care foods as anti hyperglycemic agent for prevention and treatment of post prandial hyperglycemia, hyperglycemia and related conditions in diabetes mellitus, obesity and disease conditions requiring hyperglycemic control as well as inhibition of a-glucosidase activity.
Owner:COUNCIL OF SCI & IND RES

Pharmaceutical formulation containing a biguanide and an angiotensin antagonist

A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a angiotensin antagonist is herein disclosed and described.
Owner:ANDRX LABS

Diabetes full-nutrition formula food and preparation method thereof

The invention provides a diabetes full-nutrition formula food and a preparation method thereof. The formula food comprises maltodextrin, resistant dextrin, xylitol, fruit and vegetable powder, gingerpowder, soy isolate protein, whey protein, vegetable fat powder, inulin, fructo-oligosaccharide, konjaku flour, probiotic powder, retinyl acetate, vitamin D3 powder, D-alpha-tocopheryl acetate powder,vitamin K1, thiamine hydrochloride, riboflavin, pyridoxine hydrochloride, cyanocobalamin, nicotinamide, folic acid, D-calcium pantothenate, L-sodium ascorbate, D-biotin, copper sulfate, magnesium sulfate, ferrous sulfate, zinc citrate, manganese sulfate, calcium hydrophosphate, potassium iodide, sodium selenite and potassium chloride. The diabetes full-nutrition formula food is rich in nutrition,can improve the microenvironment in the body of a patient, can resist oxidative stress of hyperglycemia on the body, and reduces body injury. The preparation method of the formula food has the advantages that the process is simple and easy to control and the formula food is suitable for wide popularization.
Owner:山东第一医科大学附属内分泌与代谢病医院

Sulfonamide compound and preparation method as well as application thereof

The invention discloses a sulfonamide compound and a preparation method as well as application thereof, and provides the sulfonamide compound with hypoglycemic activity and the preparation method thereof. The sulfonamide compound has a structure of a general formula I, wherein X is S or O atoms, n is 1, 2, 3 or 4, R1 and R2 are simultaneously or respectively hydrogen or C1-C4 alkyl groups, and R3, R4 and R5 are simultaneously or respectively one out of hydrogen, C1-C6 alkyl groups, C1-C4 alkoxyl groups, halogens, single or multi-halogen replaced C1-C4 alkyl groups, cyan, phenyl groups, single halogenated phenyl groups, C1-C4 alkoxyl phenyl group, C1-C4 alkyl sulfonyl groups and bromomethyl carbonyl groups. The sulfonamide compound with the structure of the formula I and pharmaceutically acceptable salts thereof have obvious effect in terms of resisting hyperglycemia.
Owner:TIANJIN UNIV OF COMMERCE

Anti-intussusception ileal stent and its use as an Anti-hyperglycemic method

Selected diabetic patients reveal significant glycemic control after bariatric surgical or endoscopic duodenal bypass. This controlling effect appears to occur partly because of an enhanced Glucagon-Like Peptide 1 (GLP1) release from intestinal L-cells. These procedures may also cause complications such as nutritional deficiencies. The present invention provides a stent. The method that places this stent in the ileum to activate the endogenous GLP1 release is a safer alternative to control the diabetes mellitus. However, the less mobile wall of the ileum next to the proximal stent rim can trigger an unwanted telescoping of the intestine, which is known as intussusception. An embodiment of this invention illustrates the characteristics of a stent that can prevent a likely intussusception and consequently be more confidently applied in the ileum to maintain or restore the ileal patency in general or for its anti-hyperglycemic effect in particular.
Owner:ZIAPOUR DR BEHRAD

Blood lipid reducing stone-eliminating oral liquid and its preparing method

The invention discloses a traditional Chinese medicine prescription anti-hyperglycemic calculi-dissolving oral liquid and process for preparation. Firstly, walnut kernel, sesame seed, pinenut, and hemp seed are extracted, and the grease is further stored for standby, secondly, nucleolus is extracted, the grease is stored for standby, the oil cake is dipped with grain alcohol, and is filtered, and the grain alcohol is recovered from the filter liquid and the filter liquid is condensed, thirdly, the extract oils of the walnut kernel, the sesame seed, the pinenut, and the hemp seed, the nucleolusl oil, the extract liquid of the nucleolusl oil cake, and bee honey are mixed, churned, and are hermitically encapsulated and disinfected. The invention can evidently improve bile salt density in a liner, and can evidently improve the effect of lecithine density in a liner, and has the effects of evidently reducing blood fat, dissolving and discharging calculi, curing coronary disease, and reducing pressure, and is beneficial to gallbladder.
Owner:阿来阿吉

Method for preparing dipeptidyl peptidase-IV inhibitory peptide derived from collagen of swim bladder of Nibea japonica

The invention relates to the technical field of protein extraction. In order to solve the problem that a large amount of by-products are generated during processing of Nibea japonica and the resourceutilization rate is low, the invention provides a preparation method of dipeptidyl peptidase-IV inhibitory peptide derived from collagen of swim bladder of Nibea japonica. The method comprises the following steps: (1) pretreating swim bladder of Nibea japonica, then extracting collagen with 5 wt% acetic acid combined with pepsin, and carrying out centrifugal drying to obtain collagen of swim bladder of Nibea japonica; (2) carrying out enzymolysis on the collagen of swim bladder of Nibea japonica by the use of compound enzyme so as to obtain collagen peptide of swim bladder of Nibea japonica; and (3) screening a kit by combining the collagen peptide of swim bladder of Nibea japonica with dipeptidyl peptidase so as to obtain the dipeptidyl peptidase-IV inhibitory peptide. With the swim bladder of Nibea japonica as the main raw material and through an efficient technology, the dipeptidyl peptidase-IV inhibitory peptide is prepared. The inhibitory peptide has a good effect of inhibiting dipeptidyl peptidase-4, and has a good anti-hyperglycemic effect.
Owner:ZHEJIANG OCEAN UNIV

Imide derivatives ar Salts thereof

An amide derivative represented by the following formula: wherein the ring B is a heteroaryl group; X is a bond or a lower alkylene group; and R is a hydrogen atom, a halogen atom, a lower alkyl group, an amino group, an aryl lower alkyl group or a haloaryl lower alkyl group, or a salt thereof, is disclosed. A therapeutic agent for diabetes mellitus having both an insulin secretion promoting action and an insulin sensitivity potentiating action and also having anti-obesity and anti-hyperlipemia actions due to a selective stimulating action to beta3-receptors, is also disclosed.
Owner:ASTELLAS PHARMA INC

Anti-hyperglycemic drug and preparing method thereof

The invention discloses anti-hyperglycemic drug and a preparing method thereof. The anti-hyperglycemic drug is made from coix seed, Chinese yam, astragalus root, desertliving Cistanche, fleeceflower root, honeysuckle, mulberry leaf, mulberry, chrysanthemum and wolfberry fruit according to a certain weight ratio. The anti-hyperglycemic drug has the effects of tonifying liver and kidney, inducing diuresis to alleviate edema, removing heat to cool blood and nourishing yin to promote salvia, is applicable to treatment of hyperglycemia and acts quick, with short process and no toxic or side effects.
Owner:侯德润

Pentose derivatives as anti-hyperglycemic drugs

The present invention relates to pentose and pentose derivatives that are effective at increasing glucose transport in a non-insulin dependent manner, and to uses thereof for a) treating and / or preventing hyperglycemia; b) treating and / or preventing the complications of hyperglycemia; c) treating diabetes; d) increasing the rate of cellular glucose transport; e) increasing the rate of cellular glucose uptake; f) improving the ability of a subject to metabolize glucose; g) treating daily blood glucose fluctuations; h) reducing blood sugar levels; i) reducing the dosage of anti-diabetic medication needed for treatment of diabetes. The present invention further provides novel pentose derivatives having beneficial properties in terms of pharmacokinetics, to pharmaceutical compositions comprising these novel compounds and uses thereof.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD +1

Anti-hyperglycemic steamed buns

The invention relates to the technical field of food processing, and discloses anti-hyperglycemic steamed buns. The steamed buns are characterized by being prepared from raw materials with the following parts by weight: 100 parts of flour, 7-10 parts of bitter gourd powders, 5-7 parts of maize flour, 5-7 parts of green bean powders, 3-5 parts of wolfberry powders, 0.7-0.8 part of yeast, and 55-65parts of cold water. The steamed buns are prepared as follows: grinding the raw materials; preparing mixed powders; preparing fermented dough; carrying out kneading to obtain mixed dough; preparing round unsteamed buns; steaming the round unsteamed buns; and obtaining the anti-hyperglycemic steamed buns. The anti-hyperglycemic steamed buns disclosed by the invention have the beneficial effects that the steam buns taste good, have multiple effects such as reducing blood glucose, promoting gland activities, tonifying the kidney, enriching the essence, nourishing the liver to improve the eyesight, encouraging the secretion of saliva to quench thirst and the like, can effectively enhance the human immunity, and achieve an effective dietary function for diabetes and high blood and urine glucoselevels.
Owner:李红光

Use of thiazolidinedione for preventing or retaining non-insulin-dependent diabets mellitus (NIDDM) attack

Novel methods of using thiazolidinone derivatives and related antihyperglycemic agents to treat populations experiencing impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus (NIDDM) and complications arising thereform are disclosed.
Owner:DAIICHI SANKYO CO LTD

Anti-hyperglycemic and/or anti-hyperlipidemic agent comprising material containing avian skin-derived sphingomyelin as active ingredient

Disclosed is a sphingomyelin-containing material which can be produced in a large quantity at low cost. Also disclosed is an useful use application of a sphingomyelin-containing material. Specifically disclosed is an anti-hyperglycemic and / or anti-hyperlipidemic agent comprising a material containing a sphingomyelin derived from an avain skin as an active ingredient.
Owner:MARUDAI FOOD

Synthetic process of anti-hyperglycemic drug intermediate R-3-amino-piperidine dihydrochloride

The invention relates to a synthetic process of an anti-hyperglycemic drug intermediate R-3-amino-piperidine dihydrochloride. The synthetic process comprises the steps: using inexpensive L-glutamic acid as a starting material, and performing esterification, amino protection, reduction, hydroxyl protection, substitution, cyclization and removal of protecting groups for amino groups so as to obtainthe R-3-amino-piperidine dihydrochloride. Compared with the prior art, the synthetic process has cheap and easily available raw materials, good selectivity, good atomic economy, high total yield and mild reaction conditions, and is suitable for industrial production.
Owner:苏州汉德创宏生化科技有限公司

Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity

Disclosed are the preparation and pharmaceutical use of novel noncyclic 1,3-dicarbonyl compounds of formula I, wherein ring A, ring B, R1, R2, R3, R4, R5, X, Y, Z, Q, Ar and n are as defined in the specification. These compounds, as peroxisome proliferator-activated receptor (PPAR) dual agonists for both RXR / PPARgamma and RXR / PPARalpha heterodimers, are useful in the treatment and / or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders
Owner:SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products